The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler
| ISSN: |
1432-1041
|
|---|---|
| Keywords: |
Key words Aerosols ; Ipratropium bromide
|
| Source: |
Springer Online Journal Archives 1860-2000
|
| Topics: |
Chemistry and Pharmacology
Medicine
|
| Notes: |
Abstract Objective: In previous experiments we showed that monodisperse bronchodilator aerosols with a median mass aerodynamic diameter of 2.8 μm induced stronger bronchodilatations than larger aerosols and that the dilatations were clinically relevant at low doses. To discover whether the bronchodilator effects of these low-dose monodisperse aerosols differed from those of standard dosages delivered by metered-dose inhalers, we carried out a comparative trial. Methods: Ten stable outpatients with a mean forced expiratory volume in 1 s (FEV1) of 58.1% of the predic-ted value inhaled a placebo aerosol, 8 μg of a 2.8-μm monodisperse ipratropium bromide aerosol and 40 μg from a metered-dose inhaler plus spacer; lung-function measurements followed. Data were analysed with repeated measurements analysis of variance (ANOVA). Results: Greater improvements than with placebo were evident for the forced vital capacity (FVC), the FEV1, the specific airway conductance (sGaw), the peak flow (PEF) and the maximum expiratory flow at 75% of the forced vital capacity (MEF75). In these cases, the low-dose 2.8-μm aerosol proved to be equivalent to the higher-dose metered-dose inhaler. Conclusion: By changing the polydisperse characteristic of inhaled aerosols to a monodisperse pattern, the dose of the drug administered can be reduced without loss of efficacy.
|
| Type of Medium: |
Electronic Resource
|
| URL: |
| _version_ | 1798295571049480192 |
|---|---|
| autor | Zanen, P. Go, L. T. Lammers, J.-W. J. |
| autorsonst | Zanen, P. Go, L. T. Lammers, J.-W. J. |
| book_url | http://dx.doi.org/10.1007/s002280050415 |
| datenlieferant | nat_lic_papers |
| hauptsatz | hsatz_simple |
| identnr | NLM202478319 |
| issn | 1432-1041 |
| journal_name | European journal of clinical pharmacology |
| materialart | 1 |
| notes | Abstract Objective: In previous experiments we showed that monodisperse bronchodilator aerosols with a median mass aerodynamic diameter of 2.8 μm induced stronger bronchodilatations than larger aerosols and that the dilatations were clinically relevant at low doses. To discover whether the bronchodilator effects of these low-dose monodisperse aerosols differed from those of standard dosages delivered by metered-dose inhalers, we carried out a comparative trial. Methods: Ten stable outpatients with a mean forced expiratory volume in 1 s (FEV1) of 58.1% of the predic-ted value inhaled a placebo aerosol, 8 μg of a 2.8-μm monodisperse ipratropium bromide aerosol and 40 μg from a metered-dose inhaler plus spacer; lung-function measurements followed. Data were analysed with repeated measurements analysis of variance (ANOVA). Results: Greater improvements than with placebo were evident for the forced vital capacity (FVC), the FEV1, the specific airway conductance (sGaw), the peak flow (PEF) and the maximum expiratory flow at 75% of the forced vital capacity (MEF75). In these cases, the low-dose 2.8-μm aerosol proved to be equivalent to the higher-dose metered-dose inhaler. Conclusion: By changing the polydisperse characteristic of inhaled aerosols to a monodisperse pattern, the dose of the drug administered can be reduced without loss of efficacy. |
| package_name | Springer |
| publikationsjahr_anzeige | 1998 |
| publikationsjahr_facette | 1998 |
| publikationsjahr_intervall | 8004:1995-1999 |
| publikationsjahr_sort | 1998 |
| publisher | Springer |
| reference | 54 (1998), S. 27-30 |
| schlagwort | Key words Aerosols Ipratropium bromide |
| search_space | articles |
| shingle_author_1 | Zanen, P. Go, L. T. Lammers, J.-W. J. |
| shingle_author_2 | Zanen, P. Go, L. T. Lammers, J.-W. J. |
| shingle_author_3 | Zanen, P. Go, L. T. Lammers, J.-W. J. |
| shingle_author_4 | Zanen, P. Go, L. T. Lammers, J.-W. J. |
| shingle_catch_all_1 | Zanen, P. Go, L. T. Lammers, J.-W. J. The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler Key words Aerosols Ipratropium bromide Key words Aerosols Ipratropium bromide Abstract Objective: In previous experiments we showed that monodisperse bronchodilator aerosols with a median mass aerodynamic diameter of 2.8 μm induced stronger bronchodilatations than larger aerosols and that the dilatations were clinically relevant at low doses. To discover whether the bronchodilator effects of these low-dose monodisperse aerosols differed from those of standard dosages delivered by metered-dose inhalers, we carried out a comparative trial. Methods: Ten stable outpatients with a mean forced expiratory volume in 1 s (FEV1) of 58.1% of the predic-ted value inhaled a placebo aerosol, 8 μg of a 2.8-μm monodisperse ipratropium bromide aerosol and 40 μg from a metered-dose inhaler plus spacer; lung-function measurements followed. Data were analysed with repeated measurements analysis of variance (ANOVA). Results: Greater improvements than with placebo were evident for the forced vital capacity (FVC), the FEV1, the specific airway conductance (sGaw), the peak flow (PEF) and the maximum expiratory flow at 75% of the forced vital capacity (MEF75). In these cases, the low-dose 2.8-μm aerosol proved to be equivalent to the higher-dose metered-dose inhaler. Conclusion: By changing the polydisperse characteristic of inhaled aerosols to a monodisperse pattern, the dose of the drug administered can be reduced without loss of efficacy. 1432-1041 14321041 Springer |
| shingle_catch_all_2 | Zanen, P. Go, L. T. Lammers, J.-W. J. The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler Key words Aerosols Ipratropium bromide Key words Aerosols Ipratropium bromide Abstract Objective: In previous experiments we showed that monodisperse bronchodilator aerosols with a median mass aerodynamic diameter of 2.8 μm induced stronger bronchodilatations than larger aerosols and that the dilatations were clinically relevant at low doses. To discover whether the bronchodilator effects of these low-dose monodisperse aerosols differed from those of standard dosages delivered by metered-dose inhalers, we carried out a comparative trial. Methods: Ten stable outpatients with a mean forced expiratory volume in 1 s (FEV1) of 58.1% of the predic-ted value inhaled a placebo aerosol, 8 μg of a 2.8-μm monodisperse ipratropium bromide aerosol and 40 μg from a metered-dose inhaler plus spacer; lung-function measurements followed. Data were analysed with repeated measurements analysis of variance (ANOVA). Results: Greater improvements than with placebo were evident for the forced vital capacity (FVC), the FEV1, the specific airway conductance (sGaw), the peak flow (PEF) and the maximum expiratory flow at 75% of the forced vital capacity (MEF75). In these cases, the low-dose 2.8-μm aerosol proved to be equivalent to the higher-dose metered-dose inhaler. Conclusion: By changing the polydisperse characteristic of inhaled aerosols to a monodisperse pattern, the dose of the drug administered can be reduced without loss of efficacy. 1432-1041 14321041 Springer |
| shingle_catch_all_3 | Zanen, P. Go, L. T. Lammers, J.-W. J. The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler Key words Aerosols Ipratropium bromide Key words Aerosols Ipratropium bromide Abstract Objective: In previous experiments we showed that monodisperse bronchodilator aerosols with a median mass aerodynamic diameter of 2.8 μm induced stronger bronchodilatations than larger aerosols and that the dilatations were clinically relevant at low doses. To discover whether the bronchodilator effects of these low-dose monodisperse aerosols differed from those of standard dosages delivered by metered-dose inhalers, we carried out a comparative trial. Methods: Ten stable outpatients with a mean forced expiratory volume in 1 s (FEV1) of 58.1% of the predic-ted value inhaled a placebo aerosol, 8 μg of a 2.8-μm monodisperse ipratropium bromide aerosol and 40 μg from a metered-dose inhaler plus spacer; lung-function measurements followed. Data were analysed with repeated measurements analysis of variance (ANOVA). Results: Greater improvements than with placebo were evident for the forced vital capacity (FVC), the FEV1, the specific airway conductance (sGaw), the peak flow (PEF) and the maximum expiratory flow at 75% of the forced vital capacity (MEF75). In these cases, the low-dose 2.8-μm aerosol proved to be equivalent to the higher-dose metered-dose inhaler. Conclusion: By changing the polydisperse characteristic of inhaled aerosols to a monodisperse pattern, the dose of the drug administered can be reduced without loss of efficacy. 1432-1041 14321041 Springer |
| shingle_catch_all_4 | Zanen, P. Go, L. T. Lammers, J.-W. J. The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler Key words Aerosols Ipratropium bromide Key words Aerosols Ipratropium bromide Abstract Objective: In previous experiments we showed that monodisperse bronchodilator aerosols with a median mass aerodynamic diameter of 2.8 μm induced stronger bronchodilatations than larger aerosols and that the dilatations were clinically relevant at low doses. To discover whether the bronchodilator effects of these low-dose monodisperse aerosols differed from those of standard dosages delivered by metered-dose inhalers, we carried out a comparative trial. Methods: Ten stable outpatients with a mean forced expiratory volume in 1 s (FEV1) of 58.1% of the predic-ted value inhaled a placebo aerosol, 8 μg of a 2.8-μm monodisperse ipratropium bromide aerosol and 40 μg from a metered-dose inhaler plus spacer; lung-function measurements followed. Data were analysed with repeated measurements analysis of variance (ANOVA). Results: Greater improvements than with placebo were evident for the forced vital capacity (FVC), the FEV1, the specific airway conductance (sGaw), the peak flow (PEF) and the maximum expiratory flow at 75% of the forced vital capacity (MEF75). In these cases, the low-dose 2.8-μm aerosol proved to be equivalent to the higher-dose metered-dose inhaler. Conclusion: By changing the polydisperse characteristic of inhaled aerosols to a monodisperse pattern, the dose of the drug administered can be reduced without loss of efficacy. 1432-1041 14321041 Springer |
| shingle_title_1 | The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler |
| shingle_title_2 | The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler |
| shingle_title_3 | The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler |
| shingle_title_4 | The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler |
| sigel_instance_filter | dkfz geomar wilbert ipn albert fhp |
| source_archive | Springer Online Journal Archives 1860-2000 |
| timestamp | 2024-05-06T09:38:19.269Z |
| titel | The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler |
| titel_suche | The efficacy of a low-dose, monodisperse parasympathicolytic aerosol compared with a standard aerosol from a metered-dose inhaler |
| topic | V WW-YZ |
| uid | nat_lic_papers_NLM202478319 |